This study is currently not accepting new patients, but might later

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

a study on Lung Cancer Non-Small Cell Lung Cancer Thyroid Cancer Colon Cancer Colorectal Cancer Breast Cancer Pancreatic Cancer Solid Tumor

Summary

Location
at UCLA UCSD UCSF
Dates
study started

Description

Summary

Expanded access for patients with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.

Details

N/A for expanded access

Keywords

Non Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Breast Cancer Pancreatic Cancer Papillary Thyroid Cancer Other Solid Tumors With Evidence of Activating RET Alteration Thyroid Neoplasms Thyroid Cancer, Papillary Thyroid Diseases Selpercatinib

Eligibility

You can join if…

  • Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib

You CAN'T join if...

  • Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor

Locations

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94158 United States
  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
    Torrance California 90502 United States
  • UCI Health - Chao Family Comprehensive Cancer Center
    Orange California 92868 United States

Details

Status
currently not accepting new patients, but might later
Start Date
Sponsor
Loxo Oncology, Inc.
ID
NCT03906331
Study Type
Expanded Access
Last Updated